Recombinant human interferon α2b for injection (Pseudomonas)

1. Pharmacokinetics The average serum concentration of Anfulong is the same after intramuscular and subcutaneous injection. The highest serum concentration is about 1.2-33.6 units/ml and occurs 1 to 24 hours later. The elimination half-life of Anfulong after intramuscular or subcutaneous injection is 4-12 hours, and its maximum blood concentration occurs 3.5-8 hours after administration. 2. Clinical studies Interferon α2b can make hepatitis B e antigen negative, normalize transaminase levels, reduce liver inflammation, and delay the progression to cirrhosis and improve the quality of life in 20%-30% of patients. Studies have shown that interferon α2b can normalize serum ALT, improve liver tissue and reduce the amount of virus in patients with chronic hepatitis C. Some other studies have also shown that interferon α2b has clinical significance in tumor regression or stabilization of hairy cell leukemia, and in the treatment of patients with Kaposi's sarcoma associated with AIDS. Interferon α2b is also very important for patients with chronic myeloid leukemia, and can also be used as an adjunct to intermittent treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Recombinant human interferon alpha;1b.

This product is a white, thin, loose shell. After adding 1 ml of distilled water, it dissolves into a clear liquid and contains no insoluble matter visible to the naked eye.

This product is suitable for the treatment of viral diseases and certain malignant tumors. It has been approved for the treatment of chronic hepatitis B, hepatitis C and hairy cell leukemia. Clinical trial results and literature reports have shown that it is effective in treating viral diseases such as herpes zoster, condyloma acuminatum, epidemic hemorrhagic fever and respiratory syncytial virus pneumonia in children. It can be used to treat malignant tumors such as chronic myeloid leukemia, melanoma, lymphoma, etc.

Dissolve each vial with 1 ml of sterile water for injection and inject intramuscularly or subcutaneously. The dosage and course of treatment are as follows: Chronic hepatitis B: 30~60g of this product once, once every other day, subcutaneously or intramuscularly, for a course of 4~6 months, which can be extended to 1 year depending on the condition. Induction therapy can be performed, that is, at the beginning of treatment, take the drug once a day, and change it to once every other day after 0.5~1 month until the end of the course of treatment. Chronic hepatitis C: 30~60g of this product once, once every other day, subcutaneously or intramuscularly. Treat for 4~6 months, and stop if ineffective. Those who are effective can continue treatment for up to 12 months. It can be extended to 18 months depending on the condition. In the first month of treatment, take it once a day. Follow up for 6~12 months after the end of the course of treatment. Acute hepatitis C should be treated with this product early to reduce chronicity. Chronic myeloid leukemia: 30~60g of this product once a day, subcutaneously or intramuscularly, and continue to use it for more than 6 months. It can be adjusted appropriately according to the condition, and can be changed to injection every other day after remission. Hairy cell leukemia: 30~60g of this product once, once a day, subcutaneous or intramuscular injection, continuous medication for more than 6 months. It can be adjusted according to the condition of the disease. Genital warts: 10~30g of this product once, subcutaneous or intramuscular injection, or 10g once, local injection under the wart, once every other day, 3 consecutive weeks as a course of treatment. The course of treatment can be extended or repeated according to the condition. Tumor: 30~60g of this product once, once a day or once every other day, continuous medication for more than 6 months. The course of treatment can be extended depending on the condition. If the patient does not experience rapid deterioration of the condition or serious adverse reactions, the medication should be continued at an appropriate dose.

The adverse reactions of this product are mild, the most common of which are fever, fatigue, etc., which often appear in the early stage of medication and are mostly one-time and reversible reactions; other possible adverse reactions include headache, myalgia, joint pain, loss of appetite, nausea, etc.; a few patients may experience abnormal blood counts such as leukopenia and thrombocytopenia, which can be restored after stopping the drug. If there are serious adverse reactions that the patient cannot tolerate, the dosage should be reduced or the drug should be stopped, and necessary symptomatic treatment should be given.

1. People who are known to be allergic to interferon products. 2. People with a history of angina pectoris, myocardial infarction, or other serious cardiovascular diseases. 3. People with other serious diseases who cannot tolerate the side effects of this product. 4. People with epilepsy and other central nervous system disorders.

Precautions for children: There is still limited experience in the use of this drug in children. For such cases, the drug should be used in accordance with the doctor's instructions after carefully weighing the pros and cons. Precautions for pregnancy and lactation: 1. Precautions for pregnant women are limited, and the safe use of this product during pregnancy has not yet been established. Therefore, when the condition of a pregnant woman seriously requires the use of this product, it should be carefully considered by the clinician, and it can only be used when the benefits of the drug to the mother outweigh the potential risks to the fetus. 2. There is no data showing whether interferon is secreted through breast milk after the use of this product. When breastfeeding women need to use the drug, they should consider the importance of this product to the mother to decide whether to terminate breastfeeding or stop using the drug. Precautions for the elderly: 1. For elderly patients with heart disease and advanced cancer, an electrocardiogram should be performed before and during treatment with this agent, and the dose should be adjusted or the use of this product should be stopped according to the doctor's instructions. 2. It is packaged in a controlled glass bottle or prefilled glass syringe, 1 ml each.

Sleeping pills and sedatives should be used with caution when using this product.

Store at 2-8℃ away from light.

5 million IU/vial

2 years

Harbin Pharmaceutical Group Bioengineering Co., Ltd.

• Founded in:

  1995-02-20

• Address:

  No. 99, Zhuhai Road, Limin Development Zone, Hulan District, Harbin

• Tax NO.:

  91230111128024298B

• Registered Funds:

  186.0655 million yuan

• Website:

  Log in to view

• Email:

  Log in to view